Navigation Links
Study Looks At Cost-Effectiveness of ECG in Hyperactive Kids
Date:3/8/2010

Analysis compared three strategies for preventing sudden cardiac death from stimulant medication

MONDAY, March 8 (HealthDay News) -- Electrocardiogram screening to check for heart problems in hyperactive children before prescribing stimulant medications may help identify those at risk, but is only borderline cost-effective compared to the current practice of taking a patient history and doing a physical examination, a new study shows.

Stimulant medications -- such as Ritalin, Concerta and Adderall -- that are used to treat attention-deficit/hyperactivity disorder boost pulse rate and may increase the risk of sudden cardiac death in children with some types of heart conditions.

In this study, U.S. National Institutes of Health researchers used a cost-effectiveness model to compare three strategies:

  • Strategy 1. Current standard of care -- a history, physical exam and referral of children with potential problems to a cardiologist.
  • Strategy 2. Conduct an ECG only on children with a normal history and physical, and refer those with suspicious findings on either the history/physical or ECG to a cardiologist. Compared to strategy 1, this approach would save an additional 13 children from sudden cardiac death for every 400,000 children screened. The cost would be $1.6 million per additional life saved and an estimated $39,300 per quality-adjusted life year saved.
  • Strategy 3. Conduct an ECG on all children, as well as a history and physical, and refer only those with an abnormal ECG to a cardiologist. Compared to strategy 1, this approach would also save an additional 13 children from sudden cardiac death for every 400,000 who are screened. The cost would be $1.2 million per additional life saved and about $27,200 per quality-adjusted life year saved.

Lives typically would be saved by barring at-risk children from playing sports, the researchers said.

"We're not making
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... in 2003 to slow the spiraling costs of drugs ... patients has had no meaningful impact on cancer chemotherapy ... Journal of Clinical Oncology published online today. ... treat colorectal and lung cancers, and did not find ... following the implementation of the recent Medicare law in ...
(Date:9/30/2014)... York, NY (PRWEB) September 30, 2014 ... falling demand have hampered growth in the Bread ... diets have caused consumers to moderate their consumption ... consumer preferences for premium varieties shrunk the market ... products. Successful operators proactively responded by introducing more ...
(Date:9/30/2014)... Federally Qualified Health Centers (FQHCs) granted new patient ... higher rates than other primary care practices (non-FQHCs), ... to results of a new 10-state University of ... Care . , Using data from a previous ... the investigators found that FQHCs community health ...
(Date:9/30/2014)... of allergy-related sudden deaths in the U.S., according to ... conducted by researchers at Montefiore Medical Center ... Yeshiva University . The study, published online today in ... also found that the risk of fatal drug-induced allergic ... and that such deaths increased significantly in the U.S. ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 ... Blue Star Nutraceuticals designed to help maximize lean, strong ... optimizes the body’s absorption of glucose has caught the ... , “The main purpose behind Glycodrive is to help ... lean muscle,” reports Michaels. “Carbs are essential in the ...
Breaking Medicine News(10 mins):Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2
... BFRM ) today announced its financial results for the ... of fiscal,year 2008. Net sales were $18.6 million for the ... the quarter ended December 31, 2006,an increase of $6.8 million ... ended December 31, 2007 as compared to $2.7 million for ...
... Mass., Jan. 31 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... presentation,at the 2008 Merrill Lynch Global Pharmaceutical, ... live and may be accessed by visiting ... http://www.millennium.com ., (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ...
... Jan. 31 In hopes of gaining a better,grasp ... focusing more on sales training tools and techniques to,provide ... reps,the first year of training and preparation is critical ... rep of approximately $10,500 in,the first year of employment, ...
... January 31, 2008 All candidates running for office in ... care system for the United States that is second to ... its annual report on The State of the Nations Health ... designed to gain candidate commitments to support a series of ...
... KENILWORTH, N.J., Jan. 31 Schering-Plough,Corporation (NYSE: ... antifungal agent NOXAFIL(R),(posaconazole) Oral Suspension received an ... invasive Aspergillus infections in certain,high- risk patients ... Guidelines of the Infectious Diseases Society of ...
... ovarian failure, researchers report , , THURSDAY, Jan. 31 (HealthDay ... that prompts early menopause and might account for some ... that,s known for suppressing tumor growth -- apparently also ... quickly. When researchers deleted the PTEN gene in mice, ...
Cached Medicine News:Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 2Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 3Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 4Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 5Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 6Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 7Health News:2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation 2Health News:Vital Training Tools Elevate New Pharmaceutical Sales Reps into Top Performers During Critical First Year 2Health News:Achieving a US health care system 'second to none' 2Health News:Achieving a US health care system 'second to none' 3Health News:Achieving a US health care system 'second to none' 4Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 2Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 3Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 4Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 5Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 6Health News:Study Spots Gene That Plays Role in Infertility 2
(Date:9/30/2014)...  Tasly Pharmaceuticals, Inc., the world,s leader in ... the launch of Deepure. Deepure is ... and women concerned with supporting their overall health ... while helping keep their health care cost down.  ... formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and Pro-Memory ...
(Date:9/30/2014)... 2014 Aileron Therapeutics, Inc. - Product ... Markets Direct,s, ,Aileron Therapeutics, Inc. - Product Pipeline ... Aileron Therapeutics, Inc.,s pharmaceutical research and development focus. ... current therapeutic developmental pipeline of Aileron Therapeutics, Inc.,s, ... assessment by drug target, mechanism of action (MoA), ...
(Date:9/30/2014)... , September 30, 2014 ... research report the "Glycobiology/Glycomics Market by Product [Enzymes ... MALDI-TOF), Kits, and Reagents], Application (Immunology, Oncology) ... to 2019", published by MarketsandMarkets, provides a ... challenges, opportunities, current market trends, and strategies ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... Orally Dissolving Film StripBioAlliance to Resubmit Loramyc(R) NDA WOODCLIFF ... products division of a wholly owned subsidiary of Par ... provides an update on two of its pipeline products. ... 7, 2009, Strativa submitted a New Drug Application (NDA) ...
... April 8 Phase III data, published online this ... Metabolism , showed that arzoxifene, an investigational selective estrogen ... Company (NYSE: LLY ), significantly increased lumbar ... postmenopausal women with normal or low bone mass, versus ...
Cached Medicine Technology:Strativa Pharmaceuticals Provides Product Pipeline Update 2Strativa Pharmaceuticals Provides Product Pipeline Update 3Strativa Pharmaceuticals Provides Product Pipeline Update 4Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 2Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 3Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 4
... to optimize the accuracy and precision of ... is widely recognized by customers throughout the ... over the years and now covers a ... including filter tips, certified pure tips, stepper ...
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
... racks of 96 tips, Sterilized Diamond- Tips ... Sterilized Diamond Tips are irradiated by gamma-rays ... with a certificate of sterilization, specifying the ... certified free of detectable Rnase, Dnase, DNA, ...
... of 96 tips, Sterilized Diamond- Tips are ... Diamond Tips are irradiated by gamma-rays for ... a certificate of sterilization, specifying the date ... free of detectable Rnase, Dnase, DNA, RNA, ...
Medicine Products: